A Closer Look at the White House’s Precision Medicine Initiative

McDermott Will & Emery
Contact

On January 20, 2015, as part of his State of the Union address, President Obama announced the upcoming launch of the White House’s Precision Medicine Initiative (Initiative). The Initiative seeks to allocate $215 million in 2016 toward a series of efforts aimed at collecting and using genomic, lifestyle and other clinical data in furtherance of precision medicine research. The response to the Initiative has been rapid and significant: in the short time since its announcement, a two-day workshop on the Initiative has been held, with working papers and presentations from multiple stakeholders, and an advisory committee has been formed to help develop and implement a significant portion of the Initiative. Viewed alongside other noteworthy developments from the past six months, the Initiative exemplifies current trends and challenges related to health technologies, data privacy and security, and biomedical research, and provides insight into the future of data -driven medicine.

Precision Medicine Goals -

Precision medicine is not new. Sometimes called personalized or tailored medicine, precision medicine is an approach to diagnosis and treatment that departs from the standard “one-size-fits-all” approach to care. Although some in the field argue that the difference between the terms “precision medicine” and “personalized medicine” is negligible, the term precision medicine has been actively developed and popularized within the last 10 years as a way to more accurately emphasize molecular-level information aiding patient diagnosis and treatment decisions. Precision medicine takes as its starting point the basic idea that an individual’s genetic makeup, environment, lifestyle and other patient-specific information may be predictive not only to the individual’s future health, but also to the individual’s responsiveness to treatment alternatives. For example, a precision medicine approach to treating a patient might involve genetic testing to help a treating provider determine which of several available therapeutic agents for a given condition will yield the best patient response. Precision medicine therefore prioritizes therapeutic and cost-control objectives by providing the best care quickly and without costly missteps.

Please see full publication below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDermott Will & Emery | Attorney Advertising

Written by:

McDermott Will & Emery
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

McDermott Will & Emery on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide